medical cannabis patients in the UK are encountering workplace problems that employers must address. Releaf Protect logged 114 legal support sessions between January and April 2026 for roughly 70 patients; 29% of those sessions concerned employment issues. At least nine employment cases raised discrimination, and calls about workplace matters averaged more than 16 minutes, often requiring follow-up conversations.
These numbers show disagreement and uncertainty are already producing legal disputes. Many organisational drug and alcohol policies pre-date the 2018 rescheduling of cannabis-based products for medicinal use (CBPMs) and do not mention prescribed cannabis. That omission forces managers to rely on individual judgement when employees disclose prescriptions or fail workplace drug tests.
Common workplace problems Releaf Protect reports include: dismissal or threatened termination, disputes over sick pay, requests for reasonable adjustments, absence-management processes, and employer concerns about impairment in safety-critical roles. Criminal-justice encounters made up about 25% of the helpline’s sessions, and driving-related and insurance questions were also common, showing patients often face multiple concurrent issues.
Legal framework and employer obligations Medical cannabis itself is not a protected characteristic under UK law, but many conditions treated with CBPMs—chronic pain, neurological disorders, mental health conditions—may meet the Equality Act 2010 definition of disability. Where a condition qualifies, employers must consider reasonable adjustments. Employment decisions should reflect clinical evidence, the specific job role, and occupational health input rather than assumptions about cannabis use.
Employers also retain duties to protect health and safety. Those duties require assessing impairment risk for particular tasks, especially in safety-critical roles or jobs that use heavy machinery, driving, or regulated substances. A prescription should not automatically disqualify an employee, nor should it automatically trigger disciplinary action.
Practical policy steps Employers should adopt a written medical cannabis policy that sets clear rules and consistent processes. At minimum the policy should: – Define medical cannabis: state that cannabis-based products prescribed by a specialist clinician are CBPMs and differ from recreational use. – Explain disclosure procedures: describe how employees can confidentially inform HR or occupational health about prescriptions and what documentation is acceptable. – Link to clinical and occupational advice: require case-by-case assessment with input from occupational health, the prescribing clinician (with consent), and a risk assessment for the specific role. – Update drug-testing rules: state whether routine testing detects prescribed CBPMs, how results will be interpreted, and when a positive result will trigger further assessment rather than immediate sanction. – Set guidance for safety-critical roles: detail temporary redeployment options, adjusted duties, or additional supervision where objective impairment risk is present. – Outline reasonable adjustments: provide examples (adjusted hours, phased return, remote work, temporary role changes) and a process for reviewing adjustments over time. – Protect confidentiality and prevent discrimination: remind managers of Equality Act obligations and prohibit adverse treatment solely because an employee is prescribed medicine.
Concrete examples of reasonable adjustments Employers can implement modest, measurable adjustments that reduce risk while keeping employees working. Examples include: – Temporary shift changes to avoid night driving for a specified period. – Modified duties that remove safety-critical tasks until occupational health clears return. – Adjusted start times or rest breaks to manage side effects such as drowsiness. – Phased return to full duties with review checkpoints at defined intervals.
Handling drug-test results Employers should separate detection from impairment. Urine or oral-fluid tests may detect cannabinoids long after therapeutic effects end. Where a prescribed medicine is detected, employers should: – Request evidence of a prescription and clinical context, with employee consent. – Obtain occupational health assessment focused on functional ability and safety risk. – Avoid automatic disciplinary action; base any decisions on assessment outcomes and documented risk mitigation measures.
Training and recordkeeping Train managers and HR staff to handle disclosures and test results consistently. Maintain records of assessments, adjustments, and review dates to demonstrate a fair process if disputes arise. Make sure data handling complies with confidentiality and medical-records rules.
Why action matters Employers face direct legal and operational risk if they treat all cannabis detection as misconduct or if they refuse reasonable adjustments without evidence. Releaf Protect’s data—114 sessions, 29% employment cases, multiple discrimination claims—shows a measurable increase in workplace disputes tied to CBPMs. A clear policy reduces the chance of unfair dismissal claims, discrimination complaints, and prolonged casework.
Resources and next steps Releaf has published a Medical Cannabis Employer Handbook aimed at HR teams and managers, with legal guidance, templates, and case examples. Employers should review existing drug and absence policies, consult occupational health, and adopt a written medical cannabis policy as standard practice.
Adopting explicit rules—defining prescribed CBPMs, clarifying testing interpretation, documenting risk assessments, and offering measurable reasonable adjustments—will reduce legal exposure and help employees manage long-term conditions while maintaining workplace safety and productivity.
